TIGIT Directed Human Antibody Modulates T-regulatory and Effector Cell Function

TIGIT inhibits T and NK cell function by binding CD155 and CD112, which are upregulated on tumor cells. SGN-TIGIT is fully human anti-TIGIT monoclonal antibody (mAb) that has equivalent affinity for human, murine and cynomolgus TIGIT and blocks TIGIT ligand binding. SGN-TIGIT mediates ADCC to preferentially deplete Tregs in ex-vivo PBMC cultures. SGN-TIGIT amplifies na�ve and memory CD8 T cell responses. SGN-TIGIT can result in curative single agent anti-tumor responses in several preclinical models, though its MOA appears distinct from PD-(L)1. Models enriched for activated and/or memory CD8 T cell transcripts were positively correlated with curative response.